Marinomed’s MAM-06.301 achieves preclinical proof of concept
Marinomed Biotechnologie GmbH announced that MAM-06.301 has achieved preclinical proof of concept for the treatment of allergy and allergic asthma. The study is published in BMC Immunology.
The compound, also referred to as beta-escin, was identified through screening as a potential anti-allergic compound. In the present study, MAM-06.301 was investigated in vivo in two mouse models for early and late stage allergic reactions (passive cutaneous anaphylaxis and allergic asthma). In both models beta-escin showed a potent dose-dependent inhibitory effect.
Dr Andreas Grassauer, CEO and co-founder of Marinomed, commented: “Serious allergies can be extremely debilitating life long problems and there is evidence that their incidence is increasing. The current array of treatment options such as steroids, antihistamines and mast-cell stabilizers suffer from issues of low patient compliance. We therefore hope that MAM-06.301 will be a safe alternative with high compliance in the future and plan to initiate a clinical trial in due course. ”
Original publication: Ines Lindner, Christiane Meier, Angelika Url, Hermann Unger, Andreas Grassauer, Eva Prieschl-Grassauer and Petra Doerfler; "Beta-escin has potent anti-allergic efficacy and reduces allergic airway inflammation”; BMC Immunology 2010.
Other news from the department research and development
